Methadone Blockade of Inward Rectifier Potassium Current Promotes Both Early and Delayed Repolarization Arrhythmias:...

Area of Science:

• Cardiovascular Electrophysiology
• Computational Biology
• Pharmacology

Background:

• Methadone is known to cause proarrhythmic effects by blocking various ionic currents.
• The precise mechanisms underlying methadone's proarrhythmic potential remain incompletely understood.
• Key blocked currents include the inward rectifier potassium current (I_K1), L-type calcium current, and late sodium current.

Purpose of the Study:

• To investigate the proarrhythmic mechanisms of methadone using computer simulations.
• To explore how methadone's blockade of ionic currents contributes to arrhythmogenesis, both individually and in combination.
• To elucidate the role of I_K1 blockade in methadone-induced arrhythmias.

Main Methods:

• Utilized computational simulations to model the effects of methadone on cardiac ionic currents.
• Analyzed the impact of blocking I_K1, L-type calcium current, and the rapid component of the delayed rectifier potassium current.
• Investigated synergistic effects of combined ionic current blockade and the influence of comorbid conditions like hypoxia.

Main Results:

• Blocking I_K1 potentiates QT prolongation-related arrhythmias and ectopic excitations.
• Combined blockade of I_K1 and the rapid component of the delayed rectifier potassium current shows significant synergistic effects on arrhythmia propensity.
• Blocking I_K1 with reduced L-type calcium current enhances phase 2 reentry, a mechanism linked to early repolarization and Brugada syndrome.
• Hypoxia exacerbates methadone-related arrhythmias, particularly QT prolongation and phase 2 reentry, depending on sympathetic activity.

Conclusions:

• Methadone promotes both early and delayed repolarization arrhythmias.
• Synergistic blockade of I_K1 with other channel blockers significantly increases arrhythmia risk.
• Understanding these mechanisms is crucial for managing methadone's proarrhythmic potential, especially in patients with comorbidities or on polypharmacy.